Staff Reports
CVS Health announced it is splitting into two companies, a move that breaks from the recent wave of mega-mergers in the health sector. The split is being pitched as a way to sharpen focus and unlock value, but it also raises bigger questions about consolidation, competition, and who really pays the price when healthcare gets concentrated in the hands of a few giants.
CVS is splitting — what happened
The company said it will separate its pharmacy and retail operations from its health services and insurance businesses. That means the familiar CVS drugstores will be part of one company, while the legacy Caremark pharmacy benefit manager and the Aetna insurance business will sit in the other. The separation is expected to be complete in early 2028 and, the company says, will not force store closures or change how most patients pay for prescriptions.
Why this move matters for consumers and Washington
This isn’t just corporate bookkeeping. Over the last two decades the industry has seen Caremark and CVS merge, then CVS buy Aetna, creating a conglomerate that touches almost every part of a patient’s experience — from filling a script to managing insurance claims. Critics have warned that such vertical integration can drive up costs and lock consumers into fewer choices. The split could ease some of those worries, or it could be a clever way to avoid regulatory heat while keeping the same market advantages. Investors call it “unlocking shareholder value.” Consumers call it whoever’s still paying more for less.
What conservatives should want
Conservatives should cheer competition, not corporate concentration. A breakup that leads to more rivals, clearer market signals, and lower prices is a win. But we should be suspicious of PR-friendly corporate maneuvers that leave market power intact while changing only the letterhead. Lawmakers and regulators need to stop treating consolidation as inevitable and start asking whether previous mergers actually helped patients. If they didn’t, then it’s time to hold big players accountable — not hand them the keys to ever-larger empires.
In short, CVS’s split is a development worth watching. If it restores competition and brings down costs, good. If it’s just a paper shuffle that preserves a healthcare giant’s grip on the market, taxpayers and patients will still be left holding the bill. Washington should make sure the outcome is the former — and not another victory lap for executives and shareholders at the expense of everyday Americans.
